Tailored clotting treatment may cut bleeding after heart surgery
NCT ID NCT07425600
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to find the best dose of a clotting drug (fibrinogen) for patients after heart surgery using a heart-lung machine. Bleeding is a common complication, and current dosing is not personalized. Researchers will take blood samples from 150 adults to understand how fibrinogen levels change and how to give the minimum effective dose, potentially reducing bleeding and costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fibrinogen concentrate
- What this could lead to
- If successful, this could lead to a personalized dosing strategy for fibrinogen after heart surgery, reducing bleeding and costs.
- What could go wrong
- This is an early observational study (not yet recruiting) with only 150 participants. It aims to understand variability, not to prove a new treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRINOGEN DEFICIENCY IN COMPLEX CARDIAC SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Lille
Lille, 59000, France
-
CHU de Saint-Etienne
Saint-Etienne, 42000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.